Sunday - April 05, 2026

Category Archives: Science

Amazon Bestselling Author John R. Carlos Launches a Bold Sci-Fi Trilogy That Confronts Power, Control and the Ethics of Resurrection

Discover the power within to challenge the forces of control. “Packed with heart-stopping suspense, vivid world-building, and thoughtful explorations of scientific ethics, this novel is a captivating must-read for anyone interested in the world we are all sliding towards.” – … Continue reading →

Epilepsy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Epilepsy Pipeline Insight, 2025” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epilepsy pipeline therapeutics … Continue reading →

Hemophilia A Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Hemophilia A Pipeline Insights 2025” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Hemophilia A pipeline landscape. It covers the Hemophilia A pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

COVID-19 Pipeline Insight 2025: Next-Generation Vaccines, Broad-Spectrum Antivirals, and Immunomodulators Reshape the Therapeutic Landscape | DelveInsight

COVID-19 Pipeline Insight The COVID-19 therapeutic pipeline is expanding, focusing on next-gen vaccines, broad-spectrum antivirals, and host-directed immunomodulators to tackle viral evolution and long-term effects. While first-gen vaccines and repurposed antivirals have reduced severe cases and mortality, challenges like waning … Continue reading →

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market Heats Up – Madrigal Claims European REZDIFFRA Approval as Novo Nordisk Targets US | DelveInsight

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Market Madrigal Pharmaceuticals has made a landmark entry into the European metabolic liver disease market with the European Commission (EC) approval of REZDIFFRA for adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. … Continue reading →

T-Cell Lymphoma Pipeline Insight 2025: Targeted Immunotherapies and Epigenetic Modulators Lead Innovation | DelveInsight

T-Cell Lymphoma Pipeline Insight The T-cell lymphoma treatment landscape is advancing rapidly, with growing focus on targeted immunotherapies, cell therapies, and epigenetic modulators to address resistance and improve survival. Traditional treatments like chemotherapy, stem cell transplants, and monoclonal antibodies offer … Continue reading →

Obesity Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s “Obesity Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Othe besity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics … Continue reading →

Breast Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Breast Cancer Pipeline Insight 2025” report provides comprehensive insights about 100+ Breast Cancer companies and 120+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It … Continue reading →